The genetic variants of lung adenocarcinoma includes epidermal growth factor receptor( EGFR ), Kirsten rat sarkoma virus( K-ras ), human epidermal growth factor receptor-2( HER2 ) and v-raf murine sarcoma viral oncogene homolog B1( BRAF ) related gene mutations, echinoderm microtubule-associated protein like 4/anaplastic lymphoma kinase( EML4-ALK ), the kinesin family 5B gene/receptor tyrosine kinases ( KIF5B-RET ) fusion genes.EML4-Alk fusion gene coexists with EGFR mutations and reactive oxygen species 1( ROS1) rearrangement, different gene variant patients have different therapeutic targets,and the clinical treatment and curative effect have obvious differences between individuals.Here is to make a review on the gene variants perspective, will divided lung adenocarcinoma into 9 type ( including 8 variant and one wild type ) , and the relevant targeted therapy.%肺腺癌常见的基因变异有表皮生长因子受体(EGFR)、Kirsten鼠肉瘤病毒基因(K-ras)、原癌基因人类表皮生长因子受体2(HER2)、鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)基因突变,棘皮动物微管相关类蛋白4(EML4)与间变性淋巴瘤激酶(ALK)融合基因EML4-ALK、驱动蛋白家族5B基因(KIF5B)与酪氨酸激酶受体(RET)融合基因KIF5B-RET,EGFR突变与EML4-ALK融合并存以及活性氧基团基因1(ROS1)的重排,不同的基因变异型患者存在不同的治疗靶点,临床治疗及疗效存在明显的个体差异性.该文从基因变异角度将肺腺癌分为9型(包括8种变异型和全野生型),并对其相关的靶向治疗进行综述.
展开▼
